Leading AI-driven biotech startup Galux, a specialist in de novo antibody design, announced a strategic partnership with GC Biopharma on Tuesday. This collaboration aims to accelerate the development of innovative antibody therapeutics targeting autoimmune diseases.
The agreement outlines a clear division of expertise: Galux will leverage its advanced proprietary artificial intelligence (AI) platform to design novel antibody candidates precisely optimized for specific disease-related target proteins. Concurrently, GC Biopharma will provide its extensive expertise in experimental validation, rigorously assessing the biological activity and therapeutic development potential of these candidates.
This collaborative approach will involve early-stage screening of the AI-generated candidates, followed by meticulous selection and optimization of the most promising ones. The ultimate goal is to secure highly differentiated drug candidates that address significant unmet medical needs.
This partnership with GC Biopharma underscores Galux’s broader strategic initiative to commercialize its pioneering AI-driven drug discovery capabilities through robust collaborations with leading global pharmaceutical companies. Galux currently boasts an impressive portfolio of alliances, partnering with industry giants such as Boehringer Ingelheim, Celltrion, LG Chem, HanAll Biopharma, ISU Abxis, and Y-Biologics, spanning multiple critical disease areas, including oncology and various autoimmune disorders.
Highlighting the growing industry trend, Park Tae-yong, Executive Vice President at Galux, commented, “The synergy between AI-based biotech firms and pharmaceutical companies possessing profound drug development expertise is witnessing rapid global expansion. We are actively creating real-world applications for our cutting-edge AI antibody design technology, which is pivotal in accelerating the development of truly differentiated autoimmune therapies.”
For its part, GC Biopharma affirmed its commitment to advancing next-generation antibody-based treatments. The company plans to leverage its extensive research and development (R&D) capabilities, which encompass a broad spectrum of therapeutic areas, including oncology, immunology, and rare diseases.
Jeong Jae-uk, Head of R&D at GC Biopharma, emphasized the urgency, stating, “Autoimmune diseases continue to represent an area with significant unmet medical need globally. Through this vital collaboration, our objective is to rigorously validate AI-based antibody design and ultimately develop highly differentiated therapeutics that can make a profound impact in this challenging field.”
jwjeon7625
